Sitkauskiene Brigita, Serapinas Danielius, Blanco Ignacio, Fernández-Bustillo Enrique, Janciauskiene Sabina, Sakalauskas Raimundas
Department of Pulmonology and Immunology, Kaunas University of Medicine, Eiveniu 2, LT-50009, Kaunas, Lithuania.
Respir Med. 2008 Nov;102(11):1654-8. doi: 10.1016/j.rmed.2008.07.003. Epub 2008 Aug 21.
Alpha1-antitrypsin (AAT) deficiency is an under-diagnosed condition in patients with chronic obstructive pulmonary disease (COPD). The objective of the present screening was to estimate the AAT gene frequency and prevalence and to identify AAT deficiency cases in a large cohort of Lithuanian patients with COPD.
A nationwide program of AAT deficiency was conducted in 1167 COPD patients, defined according to the GOLD criteria. Patients were collected from outpatient clinics in five different Lithuanian regions (Kaunas, Vilnius, Siauliai, Klaipeda and Alytus). AAT serum concentrations were measured by nephelometry; PI-phenotypes characterized by isoelectric-focusing.
Mean age and FEV(1) were 62.0 (10.3) and 54.7% (10.9), respectively. Ninety-one AAT deficiency genotypes (40 MZ, 39 MS, 1 SS, 3 SZ and 8 ZZ) were identified. Calculated PI()S and PI()Z frequencies, expressed in per 1000, were 18.8 (95% CI: 13.9-25) and 25.3 (95% CI: 19.4-32.7), respectively. The calculated AAT gene prevalence (Hardy-Weinberg principle) was: 1/1.09 for MM, 1/28 for MS, 1/2814 for SS, 1/20 for MZ, 1/1049 for SZ and 1/1565 for ZZ. Calculated Odds ratio (OR) for PI(*)Z in COPD vs. Lithuanian healthy people was of 1.87 (P=0.004).
The OR for each genotypic class demonstrated a significant increase of MZ, SZ and ZZ genotypes in COPD patients. The results of the present study, with a significant number of ZZ individuals detected, support the general concept of targeted screening for AAT deficiency in countries like Lithuania, with a large population of COPD patients and low awareness among care-givers about this genetic condition.
α1-抗胰蛋白酶(AAT)缺乏症在慢性阻塞性肺疾病(COPD)患者中是一种诊断不足的疾病。本筛查的目的是估计AAT基因频率和患病率,并在一大群立陶宛COPD患者中识别AAT缺乏症病例。
在1167例根据GOLD标准定义的COPD患者中开展了一项全国性的AAT缺乏症项目。患者来自立陶宛五个不同地区(考纳斯、维尔纽斯、希奥利艾、克莱佩达和阿利图斯)的门诊诊所。通过散射比浊法测量AAT血清浓度;通过等电聚焦法鉴定PI表型。
平均年龄和第一秒用力呼气容积(FEV1)分别为62.0(10.3)岁和54.7%(10.9)。鉴定出91种AAT缺乏症基因型(40种MZ、39种MS、1种SS、3种SZ和8种ZZ)。以每1000人表示的计算出的PI()S和PI()Z频率分别为18.8(95%置信区间:13.9 - 25)和25.3(95%置信区间:19.4 - 32.7)。计算出的AAT基因患病率(哈迪-温伯格原理)为:MM型为1/1.09,MS型为1/28,SS型为1/2814,MZ型为1/20,SZ型为1/1049,ZZ型为1/1565。COPD患者中PI(*)Z相对于立陶宛健康人的计算比值比(OR)为1.87(P = 0.004)。
每个基因型类别的OR显示COPD患者中MZ、SZ和ZZ基因型显著增加。本研究结果检测到大量ZZ个体,支持在立陶宛等国家对AAT缺乏症进行针对性筛查的总体概念,这些国家有大量COPD患者且护理人员对这种遗传疾病的认识较低。